Cell Reports Medicine (Aug 2020)
Systems-Level Immunomonitoring from Acute to Recovery Phase of Severe COVID-19
- Lucie Rodriguez,
- Pirkka T. Pekkarinen,
- Tadepally Lakshmikanth,
- Ziyang Tan,
- Camila Rosat Consiglio,
- Christian Pou,
- Yang Chen,
- Constantin Habimana Mugabo,
- Ngoc Anh Nguyen,
- Kirsten Nowlan,
- Tomas Strandin,
- Lev Levanov,
- Jaromir Mikes,
- Jun Wang,
- Anu Kantele,
- Jussi Hepojoki,
- Olli Vapalahti,
- Santtu Heinonen,
- Eliisa Kekäläinen,
- Petter Brodin
Affiliations
- Lucie Rodriguez
- Science for Life Laboratory, Department of Women’s and Children’s Health, Karolinska Institutet, Solna 171 77, Sweden; Corresponding author
- Pirkka T. Pekkarinen
- Division of Intensive Care Medicine, Department of Anesthesiology, Intensive Care and Pain Medicine, University of Helsinki, and Helsinki University Hospital, Helsinki 00100, Finland
- Tadepally Lakshmikanth
- Science for Life Laboratory, Department of Women’s and Children’s Health, Karolinska Institutet, Solna 171 77, Sweden
- Ziyang Tan
- Science for Life Laboratory, Department of Women’s and Children’s Health, Karolinska Institutet, Solna 171 77, Sweden
- Camila Rosat Consiglio
- Science for Life Laboratory, Department of Women’s and Children’s Health, Karolinska Institutet, Solna 171 77, Sweden
- Christian Pou
- Science for Life Laboratory, Department of Women’s and Children’s Health, Karolinska Institutet, Solna 171 77, Sweden
- Yang Chen
- Science for Life Laboratory, Department of Women’s and Children’s Health, Karolinska Institutet, Solna 171 77, Sweden
- Constantin Habimana Mugabo
- Science for Life Laboratory, Department of Women’s and Children’s Health, Karolinska Institutet, Solna 171 77, Sweden
- Ngoc Anh Nguyen
- Translational Immunology Research Program, University of Helsinki, and Helsinki University Hospital, Helsinki 00100, Finland
- Kirsten Nowlan
- Translational Immunology Research Program, University of Helsinki, and Helsinki University Hospital, Helsinki 00100, Finland
- Tomas Strandin
- Department of Virology, University of Helsinki, and Helsinki University Hospital, Helsinki 00100, Finland
- Lev Levanov
- Department of Virology, University of Helsinki, and Helsinki University Hospital, Helsinki 00100, Finland
- Jaromir Mikes
- Science for Life Laboratory, Department of Women’s and Children’s Health, Karolinska Institutet, Solna 171 77, Sweden
- Jun Wang
- Science for Life Laboratory, Department of Women’s and Children’s Health, Karolinska Institutet, Solna 171 77, Sweden
- Anu Kantele
- Inflammation Center, Division of Infectious Diseases, University of Helsinki, and Helsinki University Hospital, Helsinki 00100, Finland
- Jussi Hepojoki
- Department of Virology, University of Helsinki, and Helsinki University Hospital, Helsinki 00100, Finland
- Olli Vapalahti
- Department of Virology, University of Helsinki, and Helsinki University Hospital, Helsinki 00100, Finland
- Santtu Heinonen
- New Children’s Hospital, Pediatric Research Center, University of Helsinki, and Helsinki University Hospital, Helsinki 00100, Finland
- Eliisa Kekäläinen
- Translational Immunology Research Program, University of Helsinki, and Helsinki University Hospital, Helsinki 00100, Finland
- Petter Brodin
- Science for Life Laboratory, Department of Women’s and Children’s Health, Karolinska Institutet, Solna 171 77, Sweden; Department of Pediatric Rheumatology, Karolinska University Hospital, Solna 171 76, Sweden; Corresponding author
- Journal volume & issue
-
Vol. 1,
no. 5
p. 100078
Abstract
Summary: Severe disease of SARS-CoV-2 is characterized by vigorous inflammatory responses in the lung, often with a sudden onset after 5–7 days of stable disease. Efforts to modulate this hyperinflammation and the associated acute respiratory distress syndrome rely on the unraveling of the immune cell interactions and cytokines that drive such responses. Given that every patient is captured at different stages of infection, longitudinal monitoring of the immune response is critical and systems-level analyses are required to capture cellular interactions. Here, we report on a systems-level blood immunomonitoring study of 37 adult patients diagnosed with COVID-19 and followed with up to 14 blood samples from acute to recovery phases of the disease. We describe an IFNγ-eosinophil axis activated before lung hyperinflammation and changes in cell-cell co-regulation during different stages of the disease. We also map an immune trajectory during recovery that is shared among patients with severe COVID-19.
